Ignite Creation Date:
2024-05-06 @ 4:33 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05025735
Status:
UNKNOWN
Last Update Posted:
2021-10-19
First Post:
2021-06-26
Brief Title:
Alpelisib Fulvestrant and Dapagliflozin for the Treatment of HR HER2 - PIK3CA Mutant Metastatic Breast Cancer
Sponsor:
Saint Lukes Health System
Organization:
Saint Lukes Health System
Organization Data
Organization:
Saint Lukes Health System
Class:
OTHER
Study ID:
CBYL719A0US03T
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Saint Lukes Health System
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis Pharmaceuticals | INDUSTRY |